Clinical trials: Plasmodium Falciparum
- Condition Plasmodium Falciparum
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Malaria
Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children
This study is a single site, randomized, double-blind, placebo-controlled trial. The trial will assess the safety, tolerability, immunogenicity and vaccine efficacy (VE) of PfSPZ Vaccine in Gabonese children that are naturally…
- Trial name
- NCT03521973
- Testing
- PfSPZ Vaccine, Normal Saline
- Where
- Gabon
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Prophylaxis Against Plasmodium Falciparum Malaria
A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate
Shanghai Wanxing Bio-Pharmaceuticals is currently evaluating one malaria vaccine candidate, PfCP2.9 adjuvanted with Montanide ISA 720.
- Trial name
- NCT00284973
- Testing
- Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.
Healthy
First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants
The primary purpose of this study was to investigate the safety and tolerability of M5717 and to characterize the Pharmacokinetics (PK) /Pharmacodynamic relationship between M5717 PK and parasite clearance in healthy participants…
- Trial name
- NCT03261401
- Testing
- M5717
- Where
- Australia
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Malaria, Falciparum
First-in-Human Dose-escalation of GSK4425689A: Safety, Tolerability, and PK in Healthy Adults
This study will assess the safety, tolerability, and pharmacokinetic properties of GSK4425689A monoclonal antibody (mAb) in healthy adults, when administered by either intravenous (IV) or subcutaneous (SC) routes.
- Trial name
- NCT07646353
- Testing
- GSK4425689A SC, GSK4425689A IV
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Falciparum
A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants
The primary purpose of the study is to characterise the safety of GSK4024484 in healthy participants within a controlled pharmacokinetic (PK) range, and the effect of food on the study intervention.
- Trial name
- NCT06171113
- Testing
- GSK4024484C
- Where
- United Kingdom
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Falciparum Malaria
A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects
The study will determine if amodiaquine tablet (Pfizer), an antimalaria agent, is pharmaceutically equivalent to a comparator product (Arsuamoon-Guilin China).
- Trial name
- NCT00894660
- Testing
- Amodiaquine (Test), Amodiaquine (Comparator)
- Where
- Singapore
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Pfizer
Malaria,Falciparum
MSP3-CRM-Vac4All/ Alhydrogel® Malaria Vaccine
First-in-Human, Randomised, Dose-Finding Single Center Study to evaluate three dose levels of a novel malaria vaccine, MSP3-CRM-Vac4All/ Alhydrogel® : 3 µg, 10 µg and 30 µg
- Trial name
- MSP3CRMV4All (NCT05197751)
- Testing
- MSP3-CRM-Vac4All/ Alhydrogel®
- Where
- Mali
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Vac4All
Malaria, Falciparum
A Pharmacokinetic (PK) Trial in Healthy Asian and Caucasian Volunteers Investigating the PK Profile of Eurartesim™
The Study was designed to evaluate the pharmacokinetics of DHA and PQ in healthy volunteers and to assess the effect of ethnicity (Asian vs Caucasian), gender and body weight on the relative bioavailability of DHA and PQ.
- Trial name
- NCT01222949
- Testing
- Eurartesim
- Where
- 2 sites in Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- sigma-tau i.f.r. S.p.A.
Malaria
Clinical Performance Evaluation of Fyodor Urine Malaria Test (UMT)
The purpose of this study is to evaluate the clinical performance of the one-step Fyodor Urine Malaria Test (UMT), to determine its accuracy (sensitivity and specificity) for the diagnosis of Plasmodium falciparum malaria in…
- Trial name
- NCT01921413
- Testing
- Urine Malaria Test
- Where
- Nigeria
- Volunteers
- 1,893 people, healthy volunteers welcome
- Sponsor
- Fyodor Biotechnologies Inc
Malaria, Falciparum
A Microdose Study in Healthy Subjects to Describe Intravenous Pharmacokinetics of GSK3191607
This is an open-label, single-centre, non-randomized study to investigate the pharmacokinetics of GSK3191607, administered as a single intravenous (IV) dose in healthy male subjects.
- Trial name
- NCT02737007
- Testing
- [14C]-GSK3191607
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria
Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya
This study will be conducted in Siaya County in Nyanza Province, western Kenya. Healthy children aged 5 months through 9 years of age living within approximately 10 km of the study clinic(s) (Siaya County Referral Hospital, or…
- Trial name
- NCT02687373
- Testing
- PfSPZ Vaccine, Normal Saline
- Where
- Kenya
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Falciparum Malaria
Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects
The study will determine if artesunate tablet (Pfizer), an antimalarial agent, is pharmaceutically equivalent to Arsuamoon® tablets (Guilin-China).
- Trial name
- NCT00894374
- Testing
- Artesunate (Test), Artesunate (Comparator)
- Where
- Singapore
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer
Malaria
Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children
GSK Biologicals is developing a number of candidate malaria vaccines for the routine immunization of infants and children living in malaria-endemic areas.
- Trial name
- NCT00307021
- Testing
- GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049
- Where
- Gabon
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Plasmodium Falciparum Malaria, Malaria
Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge
The study is designed to establish infectivity of Plasmodium falciparum sporozoites (PfSPZ) via intravenous (IV) administration in three groups with different malaria immunity-status: 1.
- Trial name
- NCT02237586
- Testing
- PfSPZ Challenge
- Where
- Gabon
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria, Malaria Vaccines
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of the SB257049 candidate malaria vaccine when co-administered with Vitamin A, measles, rubella and yellow fever vaccines to children aged 6…
- Trial name
- NCT02699099
- Testing
- Vitamin A, Candidate Plasmodium falciparum malaria vaccine, MR-Vac
- Where
- 2 sites in Ghana
- Volunteers
- 699 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria Falciparum
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
This is a randomized, double-blind, placebo-controlled Phase 1 trial of Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) administered to healthy…
- Trial name
- LARC-Tu (NCT06862453)
- Testing
- PfSPZ-LARC2 Vaccine, PfSPZ Challenge (7G8)
- Where
- Germany
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria Falciparum, Malaria Infection
Age De-escalation Safety Trial of PfSPZ-LARC2 Vaccine in Burkina Faso
This is a first-in-humans randomized, double-blind, placebo-controlled, age de-escalation Phase 1 trial of Plasmodium falciparum (Pf) late liver stage-arresting replication-competent (LARC) sporozoite (SPZ) malaria vaccine…
- Trial name
- NCT06652737
- Testing
- PfSPZ-LARC2 Vaccine
- Where
- Burkina Faso
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.
Malaria, Falciparum
Safety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy Volunteers
The aim of such a study is to evaluate the impact of a therapeutic dose of Eurartesim™ compared to Riamet®, after multiple dose administration for 3 days in healthy male and female subjects on electrocardiographic parameters.
- Trial name
- NCT01103830
- Testing
- Eurartesim™, Riamet®
- Where
- France
- Volunteers
- 287 people, healthy volunteers welcome
- Sponsor
- sigma-tau i.f.r. S.p.A.
Healthy Subjects
Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects
This was a single-center study using induced blood stage malaria infection to characterize the activity of ACT-451840 against early Plasmodium falciparum blood stage infection
- Trial name
- NCT02223871
- Testing
- ACT-451840:, Plasmodium falciparum-infected human erythrocytes:, Artemether 20 mg and lumefantrine 120mg combination tablet:
- Where
- Australia
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Malaria, Plasmodium Falciparum Malaria
Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis
TÜCHMI-002 is a single center, randomized, placebo-controlled, double-blinded, PfSPZ Challenge dose finding trial with two chemoprophylactic regimens and subsequent controlled human malaria infection (CHMI).
- Trial name
- NCT02115516
- Testing
- PfSPZ Challenge
- Where
- Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Sanaria Inc.